23 reports

Top ## players hold majority of stake in the market ##.

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

AD is one of the most common types of NDDs.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

It focuses on six high priority areas such as immunology and inflammation, cardiovascular, oncology, vaccines, neurosciences, and pain.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.
  • PROVIDES A SWOT ANALYSIS OF LUNDBECK IN THE MDD MARKET.
  • LUNDBECK SWOT ANALYSIS IN MDD, 2015-2025

TRENDS IN IMMUNOLOGY; ##(##): ##-##.

  • Depression
  • Alkermes plc
  • Allergan plc
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.

The company develops products in various therapeutic areas such as oncology, immunology, diabetes, endocrinology and sedation.

  • Clinical Trial
  • Depression
  • HIV AIDS
  • United States
  • AcelRx Pharmaceuticals, Inc.
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2019

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H1 2019
  • Introduction

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2018
  • PIPELINE BY BIOCREA GMBH, H2 2018

It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.

Depression affects an estimated one in ## adults (##. ##%) per year and one in six people (##. ##%) will experience depression at some time in their life.

  • Depression
  • North America
  • United States
  • World
  • Demand

Cebranopadol is an agonist of opioid receptor like-## (ORL-##) and mu opioid receptor.

  • Depression
  • United States
  • World
  • Product Initiative
  • Grunenthal GmbH

In addition, we expect one of our principal collaborators, the U. S.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • VistaGen Therapeutics, Inc.

MDD Patient Share by Symptoms (2017) ##.

  • Depression
  • Mental Health
  • United States
  • Market Size
  • Eli Lilly & Co.
  • SCHIZOPHRENIA - PIPELINE BY F. HOFFMANN-LA ROCHE LTD
  • DEPRESSION - PIPELINE BY F. HOFFMANN-LA ROCHE LTD

It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, immunology, hematology, hemophilia and respiratory disease areas.

  • Depression
  • Pharmaceutical
  • Psychotic Disorder
  • Company
  • Product Initiative
  • Pipeline by H. Lundbeck AS, H1 2018
  • Pipeline by Johnson & Johnson, H1 2018

The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are ##, ##, ## and ## respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Bipolar Disorder
  • Clinical Trial
  • Depression
  • Neurology
  • World
  • PIPELINE BY JOHNSON & JOHNSON, H1 2018

It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and womens diseases, diabetes and vaccines.

  • Depression
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • DEPRESSION - PIPELINE BY BOEHRINGER INGELHEIM GMBH, H1 2019
  • DEPRESSION - PIPELINE BY BRISTOL-MYERS SQUIBB CO, H1 2019

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • DEPRESSION - PIPELINE BY BOEHRINGER INGELHEIM GMBH
  • DEPRESSION - PIPELINE BY BLACKTHORN THERAPEUTICS INC

ITS PRIMARY FOCUS IS ON CANCER, CARDIOVASCULAR, IMMUNOLOGY AND VIROLOGY (INCLUDING HEPATITIS B, HEPATITIS C AND HIV INFECTION) THERAPEUTIC PROJECTS.

  • Depression
  • Therapy
  • Company
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • INSOMNIA - PIPELINE BY INTRA-CELLULAR THERAPIES INC, H1 2018

In the Phase II trial ITI- ##-##, patients were randomized to receive one of four oral treatments once daily for ## weeks ## mg ITI-##, ## mg ITI-##, ## mg risperidone (positive control) or placebo in a ##:##:##:## ratio.

  • Depression
  • Sleep Aid
  • United States
  • World
  • Product Initiative
  • DEPRESSION - PIPELINE BY CALICO LLC, H2 2018
  • DEPRESSION - PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2018

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Depression
  • Therapy
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • MAJOR DEPRESSIVE DISORDER - PIPELINE BY ALKERMES PLC, H2 2016
  • AEQUUS PHARMACEUTICALS INC.

Its technology is used for the treatment of psychiatric disorders, disease intervention in addiction, behavior and mood modification, immunology, and pain.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Allergan plc

The company is also developing new therapies with focus on focus on neurology and immunology diseases.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.
  • MAJOR DEPRESSIVE DISORDER - PIPELINE BY ALKERMES PLC, H1 2016
  • ALKERMES PLC

Its technology is used for the treatment of psychiatric disorders, disease intervention in addiction, behavior and mood modification, immunology, and pain.

  • Depression
  • Research And Development
  • United States
  • Company Operations
  • Allergan plc